drugset / Trial / NCT02822599

Human Fibrinogen Concentrate in Pediatric Cardiac Surgery

NCT02822599

RandomizedParallel-groupDouble-blindPrevention

Summary

The goal of the study is to determine whether the use of Human Fibrinogen Concentrate (RiaSTAP) will decrease blood loss and the need for component blood therapy in neonates and infants undergoing cardiopulmonary bypass.

Timeline

Start
2017-06-01
Primary completion
2019-08-26
Completion
2020-12-24

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fibrinogen Concentrate Human Protein / enzyme biologic 70 mg/kg